Chondroprotective therapy and adjuvant support for patients with chronic lower back pain

Close metadata

Recommended articles:

The results of a multicenter open observational study of the efficacy and safety of the dietary supplement Neururidine N in patients with acute nonspecific lower back pain in daily outpatient practice (the NEURO-N study). S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):158-164

Successful combinations of drug and non-drug therapy for low back pain. Russian Journal of Pain. 2024;(1):57-67

Total knee replacement in different age groups. Pirogov Russian Journal of Surgery. 2024;(6):45-50

Dependence of medical rehabilitation effectiveness of patients with somatic diseases and meteopathology on features of weather-forming factors of the Moscow region. Problems of Balneology, Physiotherapy and Exercise Therapy. 2024;(3):5-12

Biotechnology in development of new treatments for osteoarthritis. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2024;(2):57-60

Disease-modifying therapy and adjuvant support in complex therapy of chronic non-specific low back pain. Resolution of the Multidisciplinary Board of Experts. Russian Journal of Pain. 2024;(3):108-116

Muscle relaxant selection criteria for musculoskeletal pain. Russian Journal of Pain. 2024;(4):55-64

The trend of an annual increase in the detection of new cases of osteoarthritis (OA) and an increase in the number of patients with chronic lower back pain (LBP) calls for the search for new drugs and pharmaconutraceuticals with anti-inflammatory and chondroprotective properties. In 2019, approaches to the treatment of pain in OA significantly changed. In international and Russian clinical guidelines (CG), pharmaconutraceutical chondroitin sulfate (CS) and glucosamine sulfate (GS) are recommended for OA of different localization as a basic therapy. CS and GS-based agents, such as Chondroguard, are symptomatic slow-acting drugs in osteoarthritis (SYSADOA) with a level of evidence of 1A. Combined pharmaconutraceuticals, including CS, GS, and undenatured type II collagen (UC-II), are a new direction in preventing OA and LBP. UC-II inhibits cartilage destruction at any stage of the disease through the mechanism of immune tolerance, which «trains» the immune system to be tolerant to the antigens of the destroyed cartilage. There is ample evidence of the successful use of pharmaconutraceuticals based on CS, GS, and UC-II molecules (Chondroguard TRIO) in patients with chronic LBP due to facet joint OA. Recent studies assessed the effect of vitamins D₃ and K₂ and their combination on OA pathogenesis. Chondroprotectors containing CS and GS combined with UC-II are actively used in clinical practice in patients with OA and LBP as part of medicine products and pharmaconutraceuticals.

Keywords:

lower back pain

osteoarthritis

chondroitin sulfate

glucosamine sulfate

undenatured type II collagen

Chondroguard

pharmaconutraceutical

Chondroguard TRIO

vitamin D3

vitamin K2

Chondroguard QUADRO

Authors:

Shavlovskaya O.A.

International University of Restorative Medicine

SPIN RSCI: 5300-4282
ORCID: 0000-0003-3726-0730

Received:

29.10.2024

Accepted:

30.10.2024

List of references:

Diamond LE, Grant T, Uhlrich SD. Osteoarthritis year in review 2023: Biomechanics. Osteoarthritis Cartilage. 2024;32(2):138-147. https://doi.org/10.1016/j.joca.2023.11.015
https://cr.minzdrav.gov.ru/recomend/778_1 https://cr.minzdrav.gov.ru/recomend/778_1
https://www.who.int/ru/publications/b/71563 https://www.who.int/ru/publications/b/71563
Davydov OS. Facet joint osteoarthritis as a component of non-specific low back pain. Neurology, Neuropsychiatry, Psychosomatics. 2019;11(2):76-82. (In Russ.). https://doi.org/10.14412/2074-2711-2019-2S-76-82
Galushko EA, Nasonov EL. Prevalence of rheumatic diseases in Russia. Almanac of Clinical Medicine. 2018;46(1):32-39. (In Russ.). https://doi.org/10.18786/2072-0505-2018-46-1-32-39
Balabanova RM, Dubinina TV. Five-year (2013-2017) trends in the incidence and prevalence of musculoskeletal system diseases among the adult population of Russia. Modern Rheumatology Journal. 2019;13(4):11-17. (In Russ.). https://doi.org/10.14412/1996-7012-2019-4-11-17
Alekseeva LI, Barantsevich ER, Vasilkin AK, et al. Resolution of the consensus of Russian Federation experts on the diagnosis and treatment of osteoarthritis for primary care physicians. Therapy. 2022;8(5(57)):119-128. (In Russ.). https://doi.org/10.18565/therapy.2022.5.119-128
Karamanos NK, Theocharis AD, Piperigkou Z, et al. A guide to the composition and functions of the extracellular matrix. FEBS J. 2021;288(24):6850-6912. https://doi.org/10.1111/febs.15776
Hua R, Ni Q, Eliason TD, et al. Biglycan and chondroitin sulfate play pivotal roles in bone toughness via retaining bound water in bone mineral matrix. Matrix Biol. 2020;94:95-109. https://doi.org/10.1016/j.matbio.2020.09.002
Alekseeva LI, Taskina EA, Kashevarova NG. Osteoarthritis: epidemiology, classification, risk factors, and progression, clinical presentation, diagnosis, and treatment. Modern Rheumatology Journal. 2019;13(2):9-21. (In Russ.). https://doi.org/10.14412/1996-7012-2019-2-9-21
Shavlovskaya OA, Sarvilina IV, Gromova OA, et al. Pharmacotherapy of pain in musculoskeletal diseases: evolution and revolution of views. Neurology, Neuropsychiatry, Psychosomatics. 2022;14(4):87-95. (In Russ.). https://doi.org/10.14412/2074-2711-2022-4-87-95
Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American College of Rheumatology / Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020;72(2):149-162. https://doi.org/10.1002/acr.24131
Kloppenburg M, Kroon F, Blanco F, et al. 2018 update of the EULAR recommendations for the management of hand osteoarthritis. Ann Rheum Dis. 2019;78(1):16-24. https://doi.org/10.1136/annrheumdis-2018-213826
Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337-50. https://doi.org/10.1016/j.semarthrit.2019.04.008
Bannuru RR, Osani MC, Vaysbrot EE, et al. OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis. Osteoarthritis Cartilage. 2019;27(11):1578-1589. https://doi.org/10.1016/j.joca.2019.06.011
National Institute for Health and Care Excellence Clinical guideline. Osteoarthritis: care and management (CG177). Published: 12 February 2014, Last updated 11 December 2020. Available from: www.nice.org.uk/guidance/cg177
https://cr.minzdrav.gov.ru/recomend/600_1 https://cr.minzdrav.gov.ru/recomend/600_1
https://cr.minzdrav.gov.ru/recomend/616_1 https://cr.minzdrav.gov.ru/recomend/616_1
https://cr.minzdrav.gov.ru/recomend/667_1 https://cr.minzdrav.gov.ru/recomend/667_1
https://cr.minzdrav.gov.ru/recomend/666_1 https://cr.minzdrav.gov.ru/recomend/666_1
Lila AM, Alekseeva LI, Taskina EA, Kashevarova NG. Modern algorithm for the treatment of osteoarthritis. Therapy. 2022;8(2(54)):65-76. (In Russ.). https://doi.org/10.18565/therapy.2022.2.65-76
Lila AM, Tkacheva ON, Naumov AV, et al. Place and role of the parenteral form of chondroitin sulfate in the treatment of osteoarthritis: multidisciplinary Consensus. RMJ. 2021;6:68-74. (In Russ.).
Torshin IYu, Lila AM, Naumov AV, et al. Meta-analysis of clinical trials of osteoarthritis treatment effectiveness with Chondroguard. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2020;13(4):388-399. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2020.066
Lila AM, Alekseeva LI, Taskina EA, et al. Clinical guidelines (project) for the diagnostics and treatment of primary osteoarthritis for primary care specialists (general practitioners, therapists). Therapy. 2023;9(1(63)):7-22. (In Russ.). https://doi.org/10.18565/therapy.2023.1.7-22
Yang W, Sun C, He SQ, et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis — systematic review and network meta-analysis. J Gen Intern Med. 2021;36(7):2085-2093. https://doi.org/10.1007/s11606-021-06755-z
Shavlovskaya OA, Gromova OA, Kochish AYu, et al. Disease-modifying osteoarthritis drugs (DMOADs): new trends in osteoarthritis therapy. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(3):482-499. (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.207
Shavlovskaya OA, Gromova OA, Torshin IYu, Romanov ID. From misconceptions to reasonable osteoarthritis patients therapy. Farmakoekonomika. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(2):317-330 (In Russ.). https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.183
Danilov AlB, Lila AM, Majidova YoN, et al. New pharmaconutraceutical Chondroguard®TRIO for the prevention of musculoskeletal diseases and nutritional support for patients with osteoarthritis and nonspecific back pain: an assessment of clinical options. Resolution of the Multidisciplinary Expert Council. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(2):134-146. (In Russ.). https://doi.org/10.14412/2074-2711-2023-2-134-146
Alekseeva LI, Barulin AE, Bakhtadze MA, et al. Place and role of disease-modifying therapy and adjuvant support in complex therapy of chronic non-specific low back pain. Resolution of the Multidisciplinary Board of Experts. Russian Journal of Pain. 2024;22(3):110-118. (In Russ.). https://doi.org/10.17116/pain202422031108
Naumov AV, Moroz VI, Khovasova NO, et al. Chronic pain in patients older than 60 years: a view of the geriatrics. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(6):53-59. (In Russ.). https://doi.org/10.17116/jnevro201911906153
Naumov AV, Khovasova NO, Moroz VI. Algorithms for managing patients over 60 years old with chronic joint and back pain. Russian Journal of Geriatric Medicine. 2021;4(8):444-450. (In Russ.). https://doi.org/10.37586/2686-8636-4-2021-444-450
Naumov AV, Khovasova NO, Moroz VI, Tkacheva ON. Falls and pathology of the musculoskeletal system in the older age groups. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(2):7-14. (In Russ.). https://doi.org/10.17116/jnevro20201200217
Naumov AV, Khovasova NO, Moroz VI, et al. The impact of osteoarthritis on the autonomy and geriatric status of patients of age 80 and older. Pallium: Palliative and Hospice Care. 2020;1(6):24-33. (In Russ.).
Mathieu S, Soubrier M, Peirs C, et al. A meta-analysis of the impact of nutritional supplementation on osteoarthritis symptoms. Nutrient. 2022;14(8):1607. https://doi.org/10.3390/nu14081607
Shavlovskaya OA, Yukhnovskaya YuD, Romanov ID, Bokova IA. Pharmaconutraceutical Chondroguard®TRIO — chondroprotector with immunomodulatory activity. Neurology, Neuropsychiatry, Psychosomatics. 2023;15(4):105-111. (In Russ.). https://doi.org/10.14412/2074-2711-2023-4-105-111
Shavlovskaya OA, Romanov ID, Bokova IA. Evidence base of pharmaconutraceuticals with chondroprotective action. Lechashchij Vrach. 2024;4(27):47-54. (In Russ.). https://doi.org/10.51793/OS.2024.27.4.007
Gencoglu H, Orhan C, Sahin E, Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. Animals. 2020;10:697. https://doi.org/10.3390/ani10040697
Shavlovskaya OA, Gromova OA, Torshin IYu. Points of undenatured type II collagen application in musculoskeletal pain syndromes treatment. S.S. Korsakov Journal of Neurology and Psychiatry. 2022;122(11):40-45. (In Russ.). https://doi.org/10.17116/jnevro202212211140
Gromova OA, Torshin IYu, Lila AM, Shavlovskaya OA. On the prospects for the use of undenatured type II collagen in the treatment of osteoarthritis and other joint diseases. Modern Rheumatology Journal. 2022;16(4):111-116. (In Russ.). https://doi.org/10.14412/1996-7012-2022-4-111-116
Shiojima Y, Takahashi M, Takahashi R, et al. Efficacy and safety of dietary undenatured type II collagen on joint and motor function in healthy volunteers: a randomized, double-blind, placebo-controlled, parallel-group study. J Am Nutr Assoc. 2022;12(7):1-18. https://doi.org/10.1080/07315724.2021.2024466
He Q, Lin Y, Chen B, et al. Vitamin K2 ameliorates osteoarthritis by suppressing ferroptosis and extracellular matrix degradation through activation GPX4’s dual functions. Biomed Pharmacother. 2024:175:116697. https://doi.org/10.1016/j.biopha.2024.116697
Chevalley T, Brandi ML, Cashman KD, et al. Role of vitamin D supplementation in the management of musculoskeletal diseases: update from an European Society of Clinical and Economical Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) working group. Aging Clin Exp Res. 2022;34(11):2603-23. https://doi.org/10.1007/s40520-022-02279-6
Charoenngam N. Vitamin D and rheumatic diseases: a review of clinical evidence. Int J Mol Sci. 2021;22:10659. https://doi.org/10.3390/ijms221910659
Capozzi A, Scambia G, Lello S. Calcium, vitamin D, vitamin K2 and magnesium supplementation and skeletal health. Maturitas. 2020;140:55-63. https://doi.org/10.1016/j.maturitas.2020.05.020
Ma M-L, Ma Z-J, He Y-L, et al. Efficacy of vitamin K2 in the prevention and treatment of postmenopausal osteoporosis: A systematic review and meta-analysis of randomized controlled trials. Front Public Health. 2022;10:979649. https://doi.org/10.3389/fpubh.2022.979649

Close metadata